Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at firstname.lastname@example.org if you need assistance.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move
across top level links and expand / close menus in sub levels. Up and Down arrows will open main level
menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab
will move on to the next part of the site rather than go through menu items.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
For 20 years, our flagship publication, Fundamentals of US Regulatory Affairs, has been giving regulatory professionals the insights and answers they need, right at their fingertips.
There are hundreds of RAC testing centers available worldwide. Any of the four RAC exams (US, EU, CAN or Global) may be taken at any location. Find an upcoming exam at a location near you.
Posted 19 October 2012 | By Alexander Gaffney, RAC
Regulatory Focus is proud to bring you another edition of Week in Review-a recap of the global regulatory news space for the preceding week. We cover news and regulatory intelligence from around the globe and bring it to you in one organized location. If you read just one thing this week, make it Regulatory Focus' Week in Review.
The US Food and Drug Administration's (FDA) problems continue to mount as an outbreak of meningitis linked to vials of a steroid medication manufactured at a compounding pharmacy in Massachusetts continues to make ill hundreds of patients. Legislators tore into the agency this week, calling on it to release all records related to its investigations and oversight of the company-a possible preclude to a congressional hearing.
On the medical device front, FDA released three new guidance documents: two for review times under the Medical Device User Fee Act and a third pertaining to a soon-to-be-mandatory electronic submission program known as eCopy. On the pharmaceutical front, Bloomberg reported FDA is strongly considering a new paradigm for approving on a limited basis drugs with the potential to address public health needs such as obesity.
In the EU, European Commision (EC) Health Commissioner John Dalli was forced to resign due to a scandal in which he is alleged to have known about tobacco companies trading favors with government regulators. The UK's Medicines and Healthcare product Regulatory Agency (MHRA) meanwhile appointed a new head of its medical devices unit, while the European Medicines Agency (EMA) released a new guideline on acute heart failure therapies.
India, perhaps more than any other country, dominated the news cycle this week, with its regulators noting their intent to ban the introduction of branded generic medications in the country in the near future. In an unrelated move, Abbott Healthcare said it was suspending a marketing program in the country critics contended was an illegal effort to pay off doctors with items in return for prescriptions.
Tags: Regulatory News, Links, Week in Review, Latest News, regulatory
Regulatory Focus newsletters
All the biggest regulatory news and happenings.
This article provides a variety of websites with important information on recent changes to FDA guidances and tables ...